Lipella Pharmaceuticals Expands its Advisory Board to Include Oncology Expertise
17 avr. 2024 08h00 HE
|
Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals Expands its Advisory Board to Include Oncology Expertise
Lipella Pharmaceuticals to Publish Abstract Detailing Compelling Preclinical Support for New Product Candidate at ASCO 2024
05 avr. 2024 08h00 HE
|
Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals to Publish Abstract Detailing Compelling Preclinical Support for New Product Candidate at ASCO 2024
Lipella Pharmaceuticals Announces FDA Type C Meeting for LP-10 for Hemorrhagic Cystitis
03 avr. 2024 08h00 HE
|
Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals Announces FDA Type C Meeting for LP-10 for Hemorrhagic Cystitis
Lipella Pharmaceuticals Announces FDA Clearance of IND for LP-410 for Oral Graft-Versus-Host Disease, Advancing Clinical Pipeline
05 mars 2024 08h00 HE
|
Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals Announces FDA Clearance of IND for LP-410 for Oral Graft-Versus-Host Disease, Advancing Clinical Pipeline
Lipella Pharmaceuticals to Present at PropThink Digital Investor Conference
20 févr. 2024 08h00 HE
|
Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals to Present at PropThink Digital Investor Conference
Lipella Pharmaceuticals Marks Successful First Year with Strategic Progress and Key Milestones Accomplished
20 déc. 2023 08h00 HE
|
Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals Marks Successful First Year with Strategic Progress and Key Milestones Accomplished